+

WO2009110010A2 - Forme posologique orale stable - Google Patents

Forme posologique orale stable Download PDF

Info

Publication number
WO2009110010A2
WO2009110010A2 PCT/IN2009/000163 IN2009000163W WO2009110010A2 WO 2009110010 A2 WO2009110010 A2 WO 2009110010A2 IN 2009000163 W IN2009000163 W IN 2009000163W WO 2009110010 A2 WO2009110010 A2 WO 2009110010A2
Authority
WO
WIPO (PCT)
Prior art keywords
dosage form
solid dosage
stable
amlodipine
oral
Prior art date
Application number
PCT/IN2009/000163
Other languages
English (en)
Other versions
WO2009110010A3 (fr
Inventor
Vaishali Vijay Dhavse
Nitin Bhalachandra Dharmadhikari
Original Assignee
Sun Pharmaceutical Industries Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Industries Ltd. filed Critical Sun Pharmaceutical Industries Ltd.
Publication of WO2009110010A2 publication Critical patent/WO2009110010A2/fr
Publication of WO2009110010A3 publication Critical patent/WO2009110010A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Definitions

  • the present invention relates to a stable, oral dosage form comprising therapeutically effective amounts of amlodipine or its pharmaceutically acceptable salt and olmesartan or its pharmaceutically acceptable salt
  • calcium channel blockers and angiotensin II receptor antagonists are widely used clinically as medicaments for the treatment and prophylaxis of hypertension.
  • United States patent application number US200602S2805 (herein after referred to as '805) relates to a pharmaceutical composition comprising pharmaceutically effective amounts of the following active ingredients:
  • an angiotensin II receptor antagonist which is (5-methyl-2-oxo-l,3-dioxolen-4-yl) methyl $-(l-hydroxy-l-methylethyl)-2-propyl-[[2'-(lh-tetrazol-5-yl)biphenyl-4-yl)methyl]imidadol-5- carboxylate and
  • (B) a calcium channel blocker is amlodipine.
  • an angiotensin II receptor antagonist selected from the group consisting of a compound having a formula (I), a pharmacologically acceptable ester thereof and a pharmacologically acceptable salt thereof;
  • a calcium channel blocker selected from the group consisting of 1,4-dihydropyridine compound and a pharmacologically acceptable salt thereof.
  • PCT patent publication, WO200700106S (hereinafter referred to as publication '06S) disclosed that prior art compositions made by direct compression had poor dissolution characteristics and claims a method comprising a step of preparing by wet granulation, a composition comprising an angiotensin II receptor antagonist and a calcium channel blocker to achieve improved dissolution of angiotensin II receptor antagonist.
  • PCT patent publication, WO2007001066 (hereinafter referred to as publication '066) claims a pharmaceutical composition comprising an angiotensin II receptor antagonist, a calcium channel blocker and at least one substance selected from a hydrophilic polymer, an acidic substance and a fluidizing agent.
  • composition in the form of tablets may be made by any method known in the art including direct compression:
  • PCT patent publication, WO2007001067 claims a solid dosage form with improved dissolution wherein the angiotensin II receptor antagonist and the calcium channel blocker are not intimately mixed rather each of the active ingredient is mixed separately with pharmaceutical excipients and isolated from each other by granulation or compression of at least one or both the mixtures.
  • the compositions can be made in the form of tablets by any of the methods known in the art including direct compression.
  • the publication '107 also claims a solid dosage form comprising olmesartan medoxomil and amlodipine or its pharmacologically acceptable salts thereof, having less than 0.4 % concentration (w/w) of 3-ethyl-S- methyl-2-[ (2-aminoethoxy)methyl]-4- (2-chloroophenyl)-6-methylpyridine-3,5-dicarobxylate (Impurity D).
  • the publication further claims a solid dosage form comprising olmesartan medoxomil and amlodipine or its pharmacologically acceptable salts thereof, having less than S.I % concentration (w/w) of total impurities.
  • the solid dosage form of the invention comprises olmesartan medoxomil and amlodipine or a pharmaceutically acceptable salt thereof, which are characterized by having less than 2.5 % concentration (w/w) of RNH-6270, less than 0.4 % concentration (w/w) of impurity D and less than 5.1 % concentration (w/w) of total impurities and by being substantially free of reducing sugar.
  • the present invention provides a stable, oral, solid dosage form consisting essentially of an intimate mixture of therapeutically effective amounts of amlodipine or its pharmaceutically acceptable salt and therapeutically effective amounts of olmesartan or its pharmaceutically acceptable salt and pharmaceutically acceptable disintegrants, diluents and lubricants, the solid dosage form being free of hydrophilic or hydrophobic binders.
  • the present invention also provides a stable, oral, solid dosage form comprising therapeutically effective amounts of amlodipine or its pharmaceutically acceptable salt and therapeutically effective amounts of olmesartan or its pharmaceutically acceptable salt, one or more antioxidants and pharmaceutically acceptable disintegrants, diluents and lubricants.
  • the present invention further provides a stable, oral solid dosage form consisting essentially of an intimate mixture of therapeutically effective amounts of amlodipine or its pharmaceutically acceptable salt and therapeutically effective amounts of olmesartan or its pharmaceutically acceptable salt and pharmaceutically acceptable disintegrants, diluents and lubricants and wherein the solid dosage form is prepared by slugging.
  • the present invention provides a stable, oral, solid dosage form consisting essentially of an intimate mixture of therapeutically effective amounts of amlodipine or its pharmaceutically acceptable salt and therapeutically effective amounts of olmesartan or its pharmaceutically acceptable salt and one or more pharmaceutically acceptable diluents, disintegrants and lubricants, the said solid dosage form being free of hydrophilic or hydrophobic binders.
  • the present invention also provides a stable, oral, solid dosage form comprising therapeutically effective amounts of amlodipine or its pharmaceutically acceptable salt and therapeutically effective amounts of olmesartan or its pharmaceutically acceptable salt, one or more antioxidants and pharmaceutically acceptable disintegrants, diluents and lubricants.
  • the present invention further provides a stable, oral solid dosage form consisting essentially of an intimate mixture of therapeutically effective amounts of amlodipine or its pharmaceutically acceptable salt and therapeutically effective amounts of olmesartan or its pharmaceutically acceptable salt and pharmaceutically acceptable disintegrants, diluents and lubricants and wherein the solid dosage form is prepared by slugging.
  • the present invention provides dosage forms having adequate rates of dissolution and chemical stability of both amlodipine besylate and olmesartan medoxomil.
  • the term 'adequate rate of dissolution' as used herein means that the dissolution of each active ingredient is more than 80 % in about 45 minutes.
  • the term 'without appreciable degradation* as used herein generally, means that the total impurities of active ingredients and known impurities do not exceed the acceptable limits of the labeled amount of active ingredient during the shelf life of the product or when kept at accelerated stability conditions for example, at 40 ° C ⁇ 2 ° C and 75 % ⁇ 5 % relative humidity for a period of three months in closed containers, with or without desiccants.
  • Amlodipine is known to be very hygroscopic and known to degrade via a catalytic oxidative route to form Impurity D (II). It was found that the composition of the present invention showed less than 0.2 % of Impurity D (II) during the shelf life of the product
  • Amlodipine used in the solid dosage form of the present invention can be used as a pharmaceutically acceptable salt such as a besylate, maleate, fumarate, camsylate, hydrochloride, hydrobromide, lactate, tartarate, citrate, mesylate, nicotinate, gluconate and the like, as well as in the form of a free base.
  • amlodipine besylate is used.
  • the amount of amlodipine besylate used in the dosage form of the present invention ranges from about 1 mg to about 100 mg by weight the dosage form.
  • the amount of olmesartan medoxomil used in the dosage form of the present invention ranges from about 1 mg to about 100 mg.
  • the amount of amlodipine besylate ranges from about 5 mg to about 20 mg and the amount of olmesartan medoxomil ranges from about 10 mg to about SO mg per unit dosage form.
  • amlodipine or its pharmaceutically acceptable salt are 'intimately mixed' together.
  • 'intimately mixed' means that the two drugs are mixed and blended and are capable of coming in contact with each other.
  • the oral, solid, dosage form of the present invention is free of hydrophilic or hydrophobic binders.
  • the term 'binder' used herein is known in the art and connotes an excipient that promotes binding of particles to form strong aggregates such as granules, pellets, slugs, pills or tablets.
  • hydrophilic binders include, but are not limited to, cellulose derivatives such as low molecular weight grades of hydroxypropyl methyl cellulose, methyl cellulose, hydroxypropyl cellulose and sodium carboxymethyl cellulose; synthetic polymers such as polyvinylpyrrolidone, aminoalkyl methacrylate copolymer, carboxyvinyl polymer, polyvinyl alcohol and polyethylene glycol); gum Arabic, agar, gelatin and sodium alginate and mixtures thereof.
  • cellulose derivatives such as low molecular weight grades of hydroxypropyl methyl cellulose, methyl cellulose, hydroxypropyl cellulose and sodium carboxymethyl cellulose
  • synthetic polymers such as polyvinylpyrrolidone, aminoalkyl methacrylate copolymer, carboxyvinyl polymer, polyvinyl alcohol and polyethylene glycol
  • gum Arabic agar, gelatin and sodium alginate and mixtures thereof.
  • hydrophilic or hydrophobic binder does not include diluents that have the ability to consolidate upon compression, for example, directly compressible diluents such as directly compressible grades of microcrystalline cellulose, spray dried lactose, mannitol and the like.
  • the amount of diluent that may be used may range from about S % to about 95 % by weight of the oral dosage form.
  • microcrystalline cellulose is used as the diluent.
  • Microcrystalline cellulose is a purified, partially deloplymerized cellulose, that occurs as a white, odorless, tasteless and crystalline powder composed of porous particles. It is commercially available in different particle sizes and moisture grades which have different properties and specifications. It is available commercially under the brand names of Avicel * by FMC Corporation, Embocel* by Edward Mendell Co. Inc and Vicacel ® by J.E Rettenmaier and S ⁇ hne GmbH. These commercially available brands are available with varying mean particle size, and moisture content.
  • Avicel ® by FMC Corporation is available as Avicel PH-101 with a nominal mean particle size of 50 microns, Avicel PH- 102 with a nominal mean particle size of 100 microns, Avicel PH-103 with a nominal mean particle size of 50 microns and moisture content of less than 3.0 %, Avicel PH- 105 with a nominal mean particle size of 20 microns and moisture content of less than 5.0 %, Avicel PH- 112 with a nominal mean particle size of 100 microns and moisture content of less than 1.5 %, Avicel PH-113 with a nominal mean particle size of 50 microns and moisture content of less than 1.5 %, Avicel PH-200 with a nominal mean particle size of 180 microns and moisture content of less than 5.0 %, Avicel PH-301 with a nominal mean particle size of 50 microns and moisture content of less than 5.0 %, Avicel PH-302 with a nominal mean particle size of 100 microns and moisture content of less than 5.0 %
  • the Vivacel brand is available as Vivacel 101, 102, 12 and 20 with the nominal mean particle size of 50, 100, 180 and 20 microns respectively, with a moisture content of less than 5 %.
  • the microcrystalline cellulose having mean particle in the range of 150 ⁇ ms to about 200 ⁇ ms, preferably a grade having mean particle size of about 180 ⁇ ms is used.
  • the solid dosage form comprises substantial amount of a reducing agent
  • a reducing sugar is a type of sugar with an aldehyde group, which allows a sugar to act as a reducing agent, for example, in a Maillard reaction or a Benedicts reaction.
  • reducing sugars include, but are not limited to, lactose, glucose, fructose, glyceraldehyde, arabinose, mannose, galactose, maltose, xylose, cellobiose, mellibiose, maltotriose, and the like and mixtures thereof.
  • substantially amount' means amount of the reducing agent in more than 10 % by weight of the solid dosage form, preferably more than 20 % by weight of the solid dosage form.
  • disintegrants used in the oral, solid dosage form of the present invention include, but are not limited to, microcrystalline cellulose, croscarmellose sodium, cross linked polyvinyl pyrrolidone, sodium starch glycolate, starch and its derivatives such as partially gelatinized starch, low substituted hydroxyl propyl cellulose, ion exchange resins like polacrillin potassium, effervescent couple such as sodium bicarbonate and citric acid and the like and mixtures thereof.
  • One preferred embodiment of the present invention uses croscarmellose sodium as the disintegrants.
  • the amount of disintegrants that may be used ranges from about 0.1 % to about 50 % by weight of the dosage form, preferably from about 1 % to about 30 % by weight of the oral dosage form.
  • lubricants that are used in the solid dosage form of the present invention, include, but are not limited to, the group comprising of sodium lauryl sulfate, talc, magnesium stearate, sodium stearyl fumarate, stearic acid, glyceryl behenate, hydrogenated vegetable oil, zinc stearate and the like and mixtures thereof.
  • the amount of lubricants used may range from about 0.1 % to about 2 % by weight of the dosage form.
  • the oral, solid, dosage form comprises one or more antioxidants.
  • the antioxidants may be selected from the group comprising butylated hydroxy anisole, butylated hydroxy toluene, alpha tocopherol and the like and mixtures thereof.
  • the amount of butylated hydroxyl toluene that may be used in the oral solid dosage form ranges from about 0.01 % to about 2 % by weight of the unit dosage form, preferably 0.05 % to about 0.S % by weight of the unit dosage form.
  • the oral, solid dosage form of the present invention may be in the form of powders, pills, pellets, tablets, powder filled into capsules, sachets, granules, slugs, compacts.
  • the solid dosage form is in the form of compressed tablets.
  • the present invention provides dosage forms that require few steps for manufacture into tablet dosage form.
  • the present invention provides a solid oral dosage form that does not necessarily require wet granulation as a means for improving dissolution. Instead, a dry granulation or direct compression which avoids the energy intensive steps of drying and also minimizing the moisture content in the final dosage form may be utilized.
  • oral dosage form of the present invention may be prepared by any suitable method such as wet granulation, dry granulation or direct compression; dry granulation processes such as slugging and roller compaction are preferred.
  • the oral dosage form is prepared by roller compaction.
  • roller compaction the blend of powders is fed to two counter-rotating rolls which draw the powder between the rolls due to friction and compact the powder.
  • the compacts formed by roller compaction are usually referred to as 'ribbons'.
  • the ribbons are further milled into smaller granules and then may be filled into capsules, or converted into tablets by compressing the milled compacts.
  • the oral dosage form may be prepared by the process of slugging.
  • the term 'slugging* as used herein means that the intimate mixture of the two active ingredients is converted into larger particles without the use of any solvent.
  • the oral dosage form is prepared by mixing together the two drugs and the pharmaceutically acceptable excipients and converting the powder blend into slugs of sizes of, for example, about 10 mm to about 20 mm round diameter, preferably about IS mm in diameter using round punches. The slugs are further milled into smaller granules and then may be filled into capsules, or converted into tablets by compressing the milled slugs.
  • the amlodipine besylate is mixed with an alcoholic solution of butylated hydroxyl toluene (BHT).
  • BHT butylated hydroxyl toluene
  • the alcohol is evaporated to get a dry amlodipine besylate with BHT.
  • This mixture of amlodipine besylate and BHT is further mixed with olmesartan or its pharmaceutically acceptable salt to get an 'intimate mixture' of the said two drugs.
  • This intimate mixture may be further mixed with other excipients such as disintegrants, lubricants and then converted into compacts or slugs.
  • the compacts or slugs may be further milled and converted into granules. These granules may be filled into capsules, or may be compressed into tablets.
  • an inert excipient such as diluent, disintegrants or lubricant or mixtures thereof, is mixed with an alcoholic solution of butylated hydroxyl toluene.
  • the alcohol is evaporated to get a dry excipient with the antioxidant
  • This mixture of the excipient and antioxidant is further mixed with the blend of amlodipine or its pharmaceutically acceptable salt and olmesartan or its pharmaceutically acceptable salt to get an 'intimate mixture' of the said two drugs.
  • This intimate mixture may be further mixed with other excipients and converted into compacts or slugs.
  • the compacts or slugs may be further milled and converted into granules. These granules may be filled into capsules, or may be compressed into tablets.
  • Butylated hydroxyl toluene was dissolved in isopropyl alcohol. Croscarmellose sodium (half portion) was wetted with the alcoholic solution of butylated hydroxyl toluene. The wet mass was dried. The specified amounts of olmesartan medoxomil, lactose anhydrous, colloidal silicon dioxide (half amount) and microcrystalline cellulose was sifted individually through ASTM # 40 mesh and mixed and then blended for about 20 minutes. This blend was mixed with the specified amount of amlodipine besylate. The mixture was further mixed in a blender for 10 minutes. Magnesium stearate was added to the above blend and blended for further S minutes.
  • This lubricated mixture was slugged using 16 mm round plain punches at a target weight of 1400 mg.
  • the slugs were milled through clit mill fitted with 2.00 mm screen at slow speed with knives forward.
  • the remaining half portion of both croscarmellose sodium and colloidal silicon dioxide were sifted through ASTM # 40 mesh.
  • Magnesium stearate was sifted through # 80 ASTM mesh.
  • the slugs were mixed with the blend of croscarmellose sodium, colloidal silicon dioxide and lubricated with magnesium stearate and compressed into tablets using suitable punches.
  • the core tablets were coated with aqueous dispersion of Opadry II white in purified water.
  • the tablets prepared according to example 1 were subjected to in vitro dissolution in USP type 2 apparatus (paddle) in 900 ml of pH 6.8 phosphate buffer rotating at 50 rpm. The dissolution was tested in peak dissolution vessel. The results of dissolution are tabulated in Table 2a.
  • the tablets were stored in high density polyethylene bottles stoppered with CRC caps containing charcoal and silica gel dessicant at different temperature and humidity conditions.
  • the stability data given below indicates that the dosage form prepared according to example 1 was stable upon storage.
  • Butylated hydroxyl toluene was dissolved in isopropyl alcohol. Croscarmellose sodium (half portion) was wetted with the alcoholic solution of butylated hydroxyl toluene. The wet mass was dried and mixed with the specified amounts of olmesartan medoxomil, lactose anhydrous, colloidal silicon dioxide (half amount) and microcrystalline cellulose. The material was mixed in a blender for 10 minutes. Magnesium stearate was added to the above blend and blended for further 5 minutes. This material was slugged using 16 mm round plain punches at a target weight of 1400 mg. The slugs were milled through cut mill fitted with 2.00 mm screen at slow speed with knives forward.
  • the remaining half portion of croscarmellose sodium, colloidal silicon dioxide and amlodipine besylate were sifted through ASTM # 40 mesh.
  • the remaining amount of magnesium stearate was sifted through # 80 ASTM mesh.
  • the slugs were mixed with the blend of croscarmellose sodium, colloidal silicon dioxide and amlodipine besylate an lubricated with magnesium stearate and compressed into tablets using suitable punches.
  • the core tablets were coated with aqueous dispersion of Opadry II white in purified water.
  • the tablets prepared according to example 2 were subjected to in vitro dissolution in USP type 2 apparatus in 900 ml of pH 6.8 phosphate buffer rotating at 50 rpm. The dissolution was tested in peak dissolution vessel. The results of dissolution are tabulated in Table 4a.
  • magnesium stearate All the listed ingredients except magnesium stearate were sifted through 40 mesh.
  • Olmesartan medoxomil was mixed with part of following excipients: lactose anhydrous, microcrystalline cellulose, low substituted hydroxypropyl cellulose and colloidal silicon dioxide in a blender for 20 minutes. This blend was lubricated with part of sifted magnesium stearate and slugged. The slugs were milled.
  • Sifted amlodipine besylate part of the following ingredients namely microcrystalline cellulose, lactose anhydrous, colloidal silicon dioxide were mixed with the milled slugs. This blend was compressed into tablets. The cores were coated with HPMC based Opadry film coating.
  • the tablets prepared according to example 3 were subjected to in vitro dissolution in USP type 2 apparatus in 900 ml of pH 6.8 phosphate buffer rotating at 50 rpm. The dissolution was tested in peak dissolution vessel. The results of dissolution are tabulated in table 6.
  • the tablets were stored in high density polyethylene bottles stoppered with CRC caps containing charcoal and silica gel dessicant at different temperature and humidity conditions.
  • the tablets of example 4 were found to retain 94.1 % of amlodipine besylate and 95.0 % of olmesartan medoxomil upon storage at 40 0 C and 75 % relative humidity for three months.
  • the stability data given below indicates that the dosage form prepared according to example 3 was stable upon storage.
  • magnesium stearate All the listed ingredients except magnesium stearate were sifted through 40 mesh.
  • Olmesartan medoxomil was mixed with the specified amounts of following excipients: lactose anhydrous, microcrystalline cellulose and a portion of the colloidal silicon dioxide and portion of croscarmellose sodium in a blender for 20 minutes. This blend was lubricated with part of sifted magnesium stearate and slugged. The slugs were milled. Butylated hydroxy! toluene was dissolved in isopropyl alcohol. Amlodipine besylate was wetted with this solution.
  • the tablets were stored in high density polyethylene bottles stoppered with CRC caps containing charcoal and silica gel dessicant at different temperature and humidity conditions.
  • the tablets of example 4 were found to retain 94.4 % of amlodipine besylate and 93.0 % of olmesartan medoxomil upon storage at 40 0 C and 75 % relative humidity for three months.
  • the stability data given below indicates that the dosage form prepared according to example 1 was stable upon storage.
  • Table 8 b Result of the stability study
  • magnesium stearate was sifted through 40 mesh.
  • Magnesium stearate was sifted through ASTM # 60 mesh.
  • Olmesartan medoxomil was mixed with the specified amounts of following excipients: lactose anhydrous, microcrystalline cellulose and a portion of the colloidal silicon dioxide and portion of croscarmellose sodium in a blender for 20 minutes. This blend was lubricated with part of sifted magnesium stearate and slugged. The slugs were milled. Butylated hydroxy! toluene was dissolved in isopropyl alcohol. Amlodipine besylate was wetted with this solution.
  • the tablets prepared according to example 5 were subjected to in vitro dissolution in USP type 2 apparatus in 900 ml of pH 6.8 phosphate buffer rotating at 50 rpm. The dissolution was tested in peak dissolution vessel. The results of dissolution are tabulated in table 10a.
  • the tablets were stored in high density polyethylene bottles stoppered with CRC caps containing charcoal and SiIiCa 1 gel dessicant at different temperature and humidity conditions.
  • the tablets of example 5 were found to retain 97.09 % of amlodipine besylate and 95.01 % of olmesartan medoxomil upon storage at 40 0 C and 75 % relative humidity for three months.
  • the stability data given below indicates that the dosage form prepared according to example 5 was stable upon storage.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une forme posologique orale stable comportant des quantités thérapeutiquement efficaces d’amoldipine ou de son sel pharmaceutiquement acceptable et d’olmésartan ou de son sel pharmaceutiquement acceptable.
PCT/IN2009/000163 2008-03-07 2009-03-09 Forme posologique orale stable WO2009110010A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN478MU2008 2008-03-07
IN478/MUM/2008 2008-03-07

Publications (2)

Publication Number Publication Date
WO2009110010A2 true WO2009110010A2 (fr) 2009-09-11
WO2009110010A3 WO2009110010A3 (fr) 2010-01-07

Family

ID=41056433

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2009/000163 WO2009110010A2 (fr) 2008-03-07 2009-03-09 Forme posologique orale stable

Country Status (1)

Country Link
WO (1) WO2009110010A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012020368A1 (fr) * 2010-08-08 2012-02-16 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Formulations d'olmesartan
WO2016155815A1 (fr) * 2015-04-01 2016-10-06 Ceva Sante Animale Forme posologique orale solide d'amlodipine et usages vétérinaires correspondants
WO2017068532A1 (fr) * 2015-10-23 2017-04-27 Ftf Pharma Private Limited Solution orale de dérivés de dihydropyridine

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050187262A1 (en) * 2004-01-12 2005-08-25 Grogan Donna R. Compositions comprising (S)-amlodipine and an angiotensin receptor blocker and methods of their use
WO2007001066A1 (fr) * 2005-06-27 2007-01-04 Daiichi Sankyo Company, Limited Préparation pharmaceutique contenant un antagoniste du récepteur de l'angiotensine ii et un bloqueur du canal calcique

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050187262A1 (en) * 2004-01-12 2005-08-25 Grogan Donna R. Compositions comprising (S)-amlodipine and an angiotensin receptor blocker and methods of their use
WO2007001066A1 (fr) * 2005-06-27 2007-01-04 Daiichi Sankyo Company, Limited Préparation pharmaceutique contenant un antagoniste du récepteur de l'angiotensine ii et un bloqueur du canal calcique

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012020368A1 (fr) * 2010-08-08 2012-02-16 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Formulations d'olmesartan
EP2425859A1 (fr) * 2010-08-08 2012-03-07 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Formulations de l'olmesartane
WO2016155815A1 (fr) * 2015-04-01 2016-10-06 Ceva Sante Animale Forme posologique orale solide d'amlodipine et usages vétérinaires correspondants
WO2016156550A1 (fr) * 2015-04-01 2016-10-06 Ceva Sante Animale Forme galénique solide de l'amlodipine pour administration par voie orale et ses utilisations vétérinaires
AU2016239689B2 (en) * 2015-04-01 2021-06-24 Ceva Sante Animale Oral solid dosage form of amlodipine and veterinary uses thereof
US11147804B2 (en) 2015-04-01 2021-10-19 Ceva Sante Animale Oral solid dosage form of amlodipine and veterinary uses thereof
WO2017068532A1 (fr) * 2015-10-23 2017-04-27 Ftf Pharma Private Limited Solution orale de dérivés de dihydropyridine

Also Published As

Publication number Publication date
WO2009110010A3 (fr) 2010-01-07

Similar Documents

Publication Publication Date Title
AU2010213594B2 (en) Delayed release, oral dosage compositions that contain amorphous CDDO-Me
RU2423975C2 (ru) Твердая лекарственная форма олмезартана медоксомила и амлодипина
EP2229938B9 (fr) Compositions d'ézétimibe
EP1849459A1 (fr) Compositions d'ézétimibe
US20110142930A1 (en) Pharmaceutical Compositions of Atorvastatin
WO2009034541A9 (fr) Formes galéniques à libération contrôlée à base de trimétazidine
JP2012503613A (ja) コンパクト化シナカルセット
EP4074308A1 (fr) Formulation elagolix
US20080268049A1 (en) Stable Solid Dosage Forms of Amlodipine and Benazepril
WO2018199282A1 (fr) Composition pharmaceutique contenant de l'enzalutamide pouvant être administrée par voie orale
AU2013365715B2 (en) A pharmaceutical composition containing candesartan cilexetil and amlodipine
US20080305158A1 (en) Methods For the Preparation of Stable Pharmaceutical Solid Dosage Forms of Atorvastatin and Amlodipine
CN101804029A (zh) 阿托伐他汀脂质体、其制备方法及含有它的药物组合物
CA2465693A1 (fr) Compositions pharmaceutiques d'atorvastatine
WO2012136839A1 (fr) Formulation sèche et composition pharmaceutique comprenant une fésotérodine ou un sel ou un solvate de celle-ci
AU2003240164A1 (en) Extended release formulation of divalproex sodium
US20080038332A1 (en) Stable pharmaceutical formulation comprising atorvastatin calcium
WO2009110010A2 (fr) Forme posologique orale stable
TWI414310B (zh) 溶出性改善之醫藥品組成物
WO2006059217A1 (fr) Formes posologiques solides stables d'amlodipine bezylate, et procedes d'elaboration correspondants
CA2609026A1 (fr) Preparations contenant du losartan et/ou des sels de ce compose
CA2450001A1 (fr) Compositions pharmaceutiques stables a base de pravastatine
EP2839829A1 (fr) Comprimé à libération prolongée contenant de la lévodropropizine et procédé pour préparer celui-ci
WO2004075825A2 (fr) Formes posologiques d'amlodipine et leurs procedes de preparation
EP4279075B1 (fr) Composition pharmaceutique contenant de l'elagolix

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09718495

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09718495

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载